Recently, treatments for
chronic hepatitis C virus (HCV)
infection have been drastically improved by the development of direct-acting
antiviral agents. In September 2014, dual oral
therapy using
daclatasvir (DCV) and
asunaprevir (ASV) was approved for the treatment of chronic HCV
infection in Japan. We treated a patient with HCV-related
liver cirrhosis with severe leg
edema due to chronic renal dysfunction using this dual oral
therapy. Although serum
alanine aminotransferase increased rapidly during the first week of treatment, the
antiviral therapy was able to continue, and liver function recovered spontaneously. After 1 month of treatment, serum HCV
RNA became continuously undetectable, and
serum albumin level gradually increased. Throughout the
therapy, serum
creatinine level nearly normalized, and leg
edema gradually improved. These improvements continued after the combination
therapy was completed. HCV
RNA remained undetectable following the end of
therapy, and sustained virological response at 12 weeks was achieved. It has been reported that chronic HCV
infection is associated with renal dysfunction and that HCV eradication can improve it. DCV and ASV combination
therapy is safe for patients who have renal dysfunction and may be a suitable
therapy for
chronic hepatitis C patients with renal dysfunction.